Myomo Posts Q3 2025 Revenue Growth but Loss Widens

Myomo, Inc. (NASDAQ: MYO) reported third‑quarter 2025 revenue of $10.1 million, a 10% increase year‑over‑year, driven by stronger international sales and an expanded order pipeline. The company delivered 186 units of its MyoPro device, up 16% compared to the prior year. However, margins came under pressure: gross margin fell to 63.8% from 75.4% a year ago, due largely to higher materials, manufacturing overhead and costs related to its new facility. The net loss expanded to approximately $3.7 million (‑$0.09 per share) from a loss of $1 million (‑$0.03 per share) in Q3 2024. Management highlighted growth in its new O&P (orthotics & prosthetics) channel, with O&P revenues up 154% to $0.9 million during the quarter. International revenue rose 63% to $1.8 million. The firm reaffirmed its full‑year 2025 revenue guidance of $40 million to $42 million. Looking ahead, Myomo is investing in its MyoConnect program to build recurring patient referrals, expanding insurance coverage, and streamlining operations to drive scalability. Yet investors will be watching closely whether the company can improve margins and return to profitability while sustaining growth momentum. #Myomo #MedTech #Q3Earnings #HealthCareTech #SlimScan #GrowthStocks #CANSLIM